Drug products: Condylin, Condyline, Condyline®, Wartec®
ATC code: D06BB04
One study has shown better effect in self-applied treatment of condylomata acuminata in men but the clinical significance is uncertain.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of podophyllotoxin have been found. No difference between men and women has been shown for transdermal absorption in general .
The efficacy and safety of self-applied 0.5% podophyllotoxin solution has been compared with hospital-applied 25% podophyllin solution for external condylomata acuminata (anogenital warts) (138 men, 67 women). Besides the observation of the superiority of podophyllotoxin, it was also observed that the effect of podophyllotoxin treatment in men was generally superior to that achieved in women; wart clearance was observed in 53% of men and 37% of women after one week and in 86% of men and 72% of women at 5 weeks of podophyllotoxin treatment. However, a higher proportion of podophyllotoxin-treated women had been treated previously for warts, thus possibly indicating a more treatment resistant population. According to the authors, the observed sex difference may relate to the greater easiness of self-applied therapy in men or biological difference in the speed of response to treatment .
No studies with a clinically relevant sex analysis regarding adverse effects of podophyllotoxin have been found.
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2016-01-17
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson